21.87
Schlusskurs vom Vortag:
$24.27
Offen:
$23.67
24-Stunden-Volumen:
2.39M
Relative Volume:
1.44
Marktkapitalisierung:
$2.78B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-10.77
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
-9.85%
1M Leistung:
-13.04%
6M Leistung:
-24.17%
1J Leistung:
-62.79%
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
APLS
Apellis Pharmaceuticals Inc
|
21.87 | 2.78B | 715.22M | -250.10M | -205.58M | -2.03 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
2024-10-16 | Eingeleitet | William Blair | Outperform |
2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-11-09 | Eingeleitet | Goldman | Buy |
2023-11-02 | Eingeleitet | Mizuho | Neutral |
2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-08-29 | Bestätigt | Citigroup | Buy |
2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
2022-06-17 | Fortgesetzt | Stifel | Buy |
2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
2021-09-10 | Bestätigt | Credit Suisse | Neutral |
2021-09-10 | Bestätigt | Needham | Buy |
2021-09-10 | Bestätigt | Oppenheimer | Outperform |
2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
2021-08-19 | Eingeleitet | Jefferies | Buy |
2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
2021-05-21 | Eingeleitet | UBS | Buy |
2021-04-16 | Eingeleitet | Goldman | Buy |
2020-11-19 | Eingeleitet | Needham | Buy |
2020-09-01 | Eingeleitet | Stifel | Buy |
2020-07-20 | Eingeleitet | ROTH Capital | Buy |
2020-06-17 | Eingeleitet | BTIG Research | Neutral |
2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
2019-11-22 | Eingeleitet | Wedbush | Underperform |
2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
(APLS) Investment Analysis - news.stocktradersdaily.com
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN
Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail
Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan
University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy - Business Wire
Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
Apellis Pharmaceuticals executive sells shares valued at $4,542 By Investing.com - Investing.com Australia
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre - Benzinga
Apellis Pharmaceuticals Beats Investor Suit Over Eye Drug Risks - Bloomberg Law News
Apellis Pharmaceuticals executive sells shares valued at $4,542 - Investing.com India
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt - Simply Wall St
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of New York Mellon Corp - Defense World
Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews
Learn to Evaluate (APLS) using the Charts - news.stocktradersdaily.com
Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Insider Sells Thousands of Apellis Pharmaceuticals Shares! - TipRanks
Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN
HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World
Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals - Defense World
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN
Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha
UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating - Marketscreener.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World
Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World
Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):